Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance
Crossref DOI link: https://doi.org/10.1038/srep25468
Published Online: 2016-05-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wang, Yuetong
Huang, Hsin-Yi
Yang, Liu
Zhang, Zhanxia
Ji, Hongbin
Text and Data Mining valid from 2016-05-06
Version of Record valid from 2016-05-06
Article History
Received: 19 January 2016
Accepted: 18 April 2016
First Online: 6 May 2016
Competing interests
: The authors declare no competing financial interests.